[CAS NO. 130-85-8] Pamoic acid
PRODUCTS SPECIFICATIONS [130-85-8]
DESCRIPTION [130-85-8]
Overview
| MDL | MFCD00004079 |
|---|---|
| Molecular Weight | 388.38 |
| Molecular Formula | C23H16O6 |
| SMILES | OC1=C(C(O)=O)C=C2C(C=CC=C2)=C1CC3=C(O)C(C(O)=O)=CC4=C3C=CC=C4 |
Summary
IC50 & Target
EC50: 79 nM (GPR35) [1]
In Vitro
GPR35 activation by Pamoic acid may increase the phosphorylation of ERK1/2, which in turn initiates an anti-inflammatory signal by suppressing NF-κB-dependent inflammatory genes [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
In a mouse model of stroke, that GPR35 activation by Pamoic acid (s.c.; 50-100 mg/kg) is neuroprotective. Pharmacological inhibition of GPR35 reveals that Pamoic acid reduces infarcts size in a GPR35 dependent manner. Pamoic acid treatment results in a preferential increment of noninflammatory Ly-6CLo monocytes/macrophages in the ischemic brain along with the reduced neutrophil counts [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvent & Solubility
DMSO : 50 mg/mL ( 128.74 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.5748 mL | 12.8740 mL | 25.7480 mL |
| 5 mM | 0.5150 mL | 2.5748 mL | 5.1496 mL |
| 10 mM | 0.2575 mL | 1.2874 mL | 2.5748 mL |
References
- [1] Ozayra Sharmin, et al. Activation of GPR35 protects against cerebral ischemia by recruiting monocyte-derived macrophages. Sci Rep. 2020 Jun 10;10(1):9400.
- [2] Pingwei Zhao, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8.
Synonyms